MyStocks

MEMBER'S LOGINX

Invalid Username / Password

Invalid Captcha

Remember Username
Keep me signed in

(Please do not use this option on a public machine)

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Small Cap Alert:
A Strong Shadow Play on the Infra,
Construction and Manufacturing Cycle

Access Research

**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
**By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

Remind Me Later | No, Thank You

Home
Stock Quote
ZENITH DRUGS LTD.

ZENITH DRUGS LTD. Share Price (ZENI)

Here is the latest stock price and chart of ZENITH DRUGS LTD.. For more details, see the ZENITH DRUGS LTD. company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.

REFRESH

Live BSE Quotes
Not listed

Live NSE Quotes			May 20, 2026 (Close)
Price (Rs)38.85	Open (Rs) 38.90	High (Rs) 38.90	Low (Rs) 38.85
% Change-0.38	Volume 1,600	Value (Rs) 62,200	52-Week H/L 82.95 / 33.30

Change
1 Day -0.38%	1 Month -10.28%	3 Months -17.16%	1 Year -50.03%

BSE Sensex | CNX Nifty

ZENITH DRUGS LTD. Share Price Today:

ZENITH DRUGS LTD. last traded price was down 0.4% to Rs 38.9 on the NSE. The total volume of shares traded was 0.0 m.

Overall, the broader S&P BSE HEALTHCARE Index was up by 0.2%. And the benchmark NIFTY 50 was at 23,659.0 (up 0.2%).

Over the last 30 days, the ZENITH DRUGS LTD. share price is down 10.3%.

As of March 2026, company promoters held 69.98% stake in ZENITH DRUGS LTD., with no shares having been pledged. To know more, check out the latest shareholding pattern of ZENITH DRUGS LTD..

FAQs on ZENITH DRUGS LTD.

What is the ZENITH DRUGS LTD. share price today?

On the NSE, ZENITH DRUGS LTD. last traded price was down 0.4% at Rs 38.9.

What is the Dividend Yield of ZENITH DRUGS LTD.?

For the financial year 2024, ZENITH DRUGS LTD. declared dividend amounting to Rs 0.5 per share. At the current price of Rs 38.9, this results in a dividend yield of 1.3%.

Which are the top pharmaceuticals companies in India by marketcap?

Based on marketcap, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks ranked by marketcap here.

Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.

Which are the biggest pharmaceuticals companies in India by sales?

Based on sales, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks.

Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.

Which are the biggest pharmaceuticals companies in India by net profit?

Based on net profit, these are the top pharmaceuticals companies in India:

You can see the full list of pharmaceuticals stocks.

In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.

Today's Market

Lenskart Q4 Result | Rupee Hits Record Low | Top Buzzing Stocks Today(Pre-Open)

Indian markets traded positive throughout the session and ultimately closed green.

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS

QUICK LINKS

FREE NEWSLETTERS

EQUITYMASTER SUPPORTS

Registered Name:

Quantum Information Services Private Limited
Registered Office Address:

103, Regent Chambers, Nariman Point, Mumbai 400021
CIN:

U65990MH1989PTC054667
Website:

www.equitymaster.com
Compliance Officer & Grievance Officer:

Ms. Sonal Ramachandran
| Telephone No.: +91-22-61434003 | Email: compliance@equitymaster.com

SEBI Registered Research Analyst Details:

SEBI Registration No.: INH000021128 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 6769

Principal Officer: Tanushree Banerjee | Telephone No.:+91-22-61434055 | Email: po.ra@equitymaster.com

SEBI Registered Investment Adviser Details:

SEBI Registration No.: INA000000680 | Type of Registration: Non-Individual | Validity: Perpetual | BSE Enlistment No: 1488

Principal Officer: Vivek Chaurasia | Telephone No.:+91-22-61434055 | Email: po.ria@equitymaster.com

SEBI Office Details:

SEBI Bhavan BKC
Address: Plot No.C4-A, 'G' Block Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra
Telephone No.: +91-22-26449000 / 40459000 | Fax: +91-22-26449019-22 / 40459019-22 | Email: sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575
SCORES: https://www.scores.gov.in/ | SMARTODR: https://smartodr.in/login

Association of Mutual Funds of India (AMFI) Registered Details:

AMFI Registered Mutual Fund Distributor
AMFI Registration Number : ARN - 1022
Date of Initial Registration : 28 / JAN / 2008
Current Validity of ARN upto : 28 / JAN / 2028

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.

Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.

The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.

Corporate Actions